Cough hypersensitivity syndrome: a distinct clinical entity.
We postulate that most patients with chronic cough have a single discrete clinical entity: cough hypersensitivity syndrome. We constructed a questionnaire that elicits the major components of the syndrome. Here we describe the validation of this questionnaire. Following iterative development, the Hull Airway Reflux Questionnaire (HARQ) was administered to patients and normal volunteers. It is self-administered and comprises 14 items with a maximum score of 70. Unselected patients were recruited sequentially from the Hull Cough Clinic. Preclinic questionnaires were compared with those obtained at the clinic. Responsiveness was assessed 2 months after the clinic visit. One hundred eighty-five patients and 70 normal volunteers were included in this study. There was a marked difference in HARQ scores between patients with chronic cough and normal volunteers. The sensitivity (94%) and specificity (95%) of the HARQ was high, with an area under the ROC curve of 0.99. All items of the scale significantly correlated positively with others in the scale and with the total score. On repeatability testing using Cohen's kappa with quadratic weights, significant agreement was noted for all items. Good correlation was observed between the total scores (r = 0.78). The questionnaire was also responsive to treatment; the minimum clinically significant change was estimated to be 16 points. We have demonstrated the HARQ to have good construct and criterion validity. It is both reproducible and responsive to change. It can be used as a diagnostic instrument and demonstrates that chronic cough represents a single coherent entity: cough hypersensitivity syndrome.
Cardiovascular and Respiratory Studies, Castle Hill Hospital, Hull York Medical School, University of Hull, Castle Road, Cottingham, East Yorkshire HU16 5JQ, UK.
A H
AH
Morice
S
S
Faruqi
C E
CE
Wright
R
R
Thompson
J M
JM
Bland
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002648:Child; D002908:Chronic Disease; D003371:Cough / Q000145:classification* / Q000175:diagnosis / Q000628:therapy; D004739:England; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D017060:Patient Satisfaction; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011594:Psychometrics; D012372:ROC Curve; D015203:Reproducibility of Results; D012130:Respiratory Hypersensitivity / Q000145:classification* / Q000175:diagnosis / Q000628:therapy; D012680:Sensitivity and Specificity; D011795:Surveys and Questionnaires; D013577:Syndrome; D016896:Treatment Outcome; D055815:Young Adult
Am Rev Respir Dis. 1981 Apr;123(4 Pt 1):413-7
7224353
Chest. 2002 Apr;121(4):1123-31
11948042
Gut. 2001 Dec;49(6):767-72
11709509
Am J Respir Crit Care Med. 1999 Aug;160(2):406-10
10430705
Pulm Pharmacol Ther. 2002;15(3):253-9
12099774
Respir Med. 2007 Feb;101(2):345-8
16787744
N Engl J Med. 1979 Mar 22;300(12):633-7
763286
Respir Med. 1996 May;90(5):279-86
9499812
Chest. 1984 Mar;85(3):346-52
6697790
Am J Respir Crit Care Med. 2002 Oct 1;166(7):961-4
12359654
Cough. 2005 Sep 23;1:9
16270939
Thorax. 2006 Nov;61(11):975-9
16809412
Eur Respir J. 1992 Jul;5(7):841-7
1499708
Thorax. 2003 Apr;58(4):339-43
12668799
Thorax. 2009 May;64(5):393-8
19131447
Allergy. 1998 Dec;53(12):1208-12
9930599
J Voice. 2002 Jun;16(2):274-7
12150380